Healthcare -
Drug Manufacturers - General - NYSE - UK
$ 36.63
1.45 %
$ 74.2 B
Market Cap
22.09
P/E
1. INTRINSIC VALUE
Balance Sheet
GSK plc
| Current Assets | 17 B |
| Cash & Short-Term Investments | 3.71 B |
| Receivables | 0 |
| Other Current Assets | 13.3 B |
| Non-Current Assets | 42.5 B |
| Long-Term Investments | 1.21 B |
| PP&E | 10.1 B |
| Other Non-Current Assets | 31.2 B |
| Current Liabilities | 21.7 B |
| Accounts Payable | 3.46 B |
| Short-Term Debt | 2.35 B |
| Other Current Liabilities | 15.9 B |
| Non-Current Liabilities | 24.7 B |
| Long-Term Debt | 14.6 B |
| Other Non-Current Liabilities | 10 B |
EFFICIENCY
Earnings Waterfall
GSK plc
| Revenue | 31.4 B |
| Cost Of Revenue | 9.05 B |
| Gross Profit | 22.3 B |
| Operating Expenses | 18.3 B |
| Operating Income | 4.02 B |
| Other Expenses | 1.07 B |
| Net Income | 2.95 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GSK plc
| Net Income | 2.95 B |
| Depreciation & Amortization | 2.55 B |
| Capital Expenditures | -2.98 B |
| Stock-Based Compensation | 344 M |
| Change in Working Capital | 2.09 B |
| Others | 662 M |
| Free Cash Flow | 3.57 B |
Wall Street Analysts Price Targets
GSK plc
Wall Street analysts predict an average 1-year price target for GSK of $49.6 , with forecasts ranging from
a
low of
$35.2 to a high of $85 .
GSK Lowest Price Target
Wall Street Target
35.2 USD
-3.77%
GSK Average Price Target
Wall Street Target
49.6 USD
35.36%
GSK Highest Price Target
Wall Street Target
85 USD
132.05%
4. DIVIDEND
ANALYSIS
1.11%
DIVIDEND YIELD
0.401 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
GSK plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
barrons.com
- 1 week ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
fxempire.com
- 1 week ago
UK approves combination therapies of GSK's blood cancer drug Blenrep
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at least one other therapy previously.
reuters.com
- 2 weeks ago
Here's Why GSK (GSK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 2 weeks ago
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
zacks.com
- 2 weeks ago
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
zacks.com
- 2 weeks ago
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD).
globenewswire.com
- 2 weeks ago
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Arexvy--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices.
businesswire.com
- 2 weeks ago
GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK's 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices.
businesswire.com
- 2 weeks ago
GSK in breach for misleading prescribing information on Omjjara, industry body says
British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.
reuters.com
- 2 weeks ago
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
youtube.com
- 2 weeks ago
Trump says US pharma tariffs coming in not-too-distant future
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
reuters.com
- 2 weeks ago
8. Profile
Summary
GSK plc GSK
COUNTRY
UK
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 74.2 B
Dividend Yield
1.11%
Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Contact
980 Great West Road, Brentford, TW8 9GS
https://www.gsk.com
IPO
Date
March 28, 1980
Employees
68629
Officers
Mr. Tony Wood
Chief Scientific Officer and Head of R&D
Ms. Emma Natasha Walmsley
Chief Executive Officer & Director
Ms. Julie Belita Brown A.C.A.
Chief Financial Officer & Executive Director
Mr. David Simon Redfern BSc (Hons), CA
President of Corporate Development
Mr. James Ford
Senior Vice President & Group General Counsel of Legal & Compliance
Ms. Diana Conrad
Chief People Officer
Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer
Ms. Sally Jackson
Senior Vice President of Global Communications & Chief Executive Officer Office
Mr. Philip C. Thomson
President of Global Affairs
Mr. Luke V. Miels
Chief Commercial Officer